Haneen Shalabi

Statistics

Publications

Citations

3.5K

H-Index

Active since

2016

Affiliations

National Institutes of Health(Current)

National Cancer Institute

Center for Cancer Research

University of Virginia

Stanford University

Haneen Shalabi is an author at National Institutes of Health specializing in chimeric antigen receptor t-cell therapy, immunotherapy, and cell therapy.

ORCID

Publications per year

2016–2024

Publications

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry, Nirali N. Shah, Rimas J. Orentas et al. · Nature Medicine · 2017 · 1.3K citations

Life Sciences, Immunology, Oncology +14

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Nirali N. Shah, Steven L. Highfill, Haneen Shalabi et al. · Journal of Clinical Oncology · 2020 · 416 citations · Full text

Life Sciences, Hematology, Immunology +17

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Nirali N. Shah, Daniel W. Lee, Bonnie Yates et al. · Journal of Clinical Oncology · 2021 · 356 citations · Full text

Medicine, Hematology, Immunology +17

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Daniel A. Lichtenstein, Fiorella Schischlik, Lipei Shao et al. · Blood · 2021 · 189 citations · Full text

Life Sciences, Hematology, Immunology +11

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Haneen Shalabi, Haiying Qin, Angela Su et al. · Blood · 2022 · 175 citations · Full text

Life Sciences, Hematology, Immunology +17

1–5 of 29